Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis

Xin Wang, Tatiana N. Nanovskaya, Ying Zhan, Susan M. Abdel-Rahman, Marlo Jasek, Gary D.V. Hankins, Mahmoud S. Ahmed

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Objective. The present study was undertaken to investigate the pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. Methods. Twenty patients received metronidazole (Flagyl®, Pfizer, 235 East 42nd Street, NY, NY 10017) oral dose 500 mg twice a day for 3 consecutive days. Pharmacokinetic analyses of metronidazole were performed after a single oral dose on the morning of day 4. Results. Although absolute estimates of metronidazole total body exposure were highest in women during early term pregnancy, weight-corrected estimates of exposure maximum plasma drug concentration (C max) and the area under the plasma concentration-versus-time curve (AUC 0-12), along with apparent oral clearance and distribution volume, were not significantly different between women at early, middle, and late stages of pregnancy and were in the range of reported values for nonpregnant patients receiving a similar dose. Conclusions. The pharmacokinetic profile of metronidazole did not change at the different time points assessed during pregnancy.

Original languageEnglish (US)
Pages (from-to)444-448
Number of pages5
JournalJournal of Maternal-Fetal and Neonatal Medicine
Issue number3
StatePublished - Mar 2011


  • Bacterial vaginosis
  • metronidazole
  • pharmacokinetics
  • pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology


Dive into the research topics of 'Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis'. Together they form a unique fingerprint.

Cite this